During the past decade, Drug Management Only conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Drug Management Only" are "Breast Cancer" (1 trials) and "Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Drug Management Only" in a lesser frequency.

Most popular intervention types in "Drug Management Only" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Active Comparator (erlotinib)" (1 trials), "Dacomitinib (PF-00299804)" (1 trials), "PD 0332991" (1 trials), "Placebo PF00299804" (1 trials) and "Placebo erlotinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Drug Management Only" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Drug Management Only". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Drug Management Only, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Drug Management Only, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".